

**ORIGINAL ARTICLE****Immediate Outcomes of Transcatheter Closure versus Surgical Ligation of Patent Ductus Arteriosus in Children at the Cardiac Center of Ethiopia (2012-2022): A Comparative Cross-Sectional Study****Mohammed Nasir Beshir<sup>1</sup>, Muluken Ahmed<sup>2</sup>****OPEN ACCESS**

**Citation:** Mohammed Nasir Beshir-Muluken Ahmed. Immediate Outcomes of Transcatheter Closure versus Surgical Ligation of Patent Ductus Arteriosus (PDA) in Children at the Cardiac Center of Ethiopia (2012-2022): A Comparative Cross-Sectional Study. *Ethiop J Health Sci.* 2024;34(5):379. doi:<http://dx.doi.org/10.4314/ejhs.v34i5.6>

Received: April 2, 2024

Accepted: August 15, 2024

Published: September 1, 2024

**Copyright:** © 2024 Mohammed N.B., et al. This access open-article access article is distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** Nil

**Competing Interests:** The authors declare that this manuscript was approved by all authors in its form and that no competing interest exists.

**Affiliation and Correspondence:**

<sup>1</sup>Pediatric Cardiologist, Hawassa University, Hawassa

<sup>2</sup>Pediatrician, Arba Minch University, Arba Minch

Email: [ahmedmuluken@yahoo.com](mailto:ahmedmuluken@yahoo.com)

**ABSTRACT**

**BACKGROUND:** *Transcatheter closure and surgical ligation of patent ductus arteriosus (PDA) are management options for PDA that have not spontaneously closed. However, studies reported the presence of complications and residual shunts in both transcatheter closure and surgical ligation of PDA by themselves. In this study, the immediate outcomes of transcatheter closure of PDA versus surgical ligation of PDA were compared.*

**METHODS:** *Comparative cross-sectional study conducted on children under 18 years of age who underwent transcatheter closure and surgical ligation of PDA at a cardiac center in Ethiopia from January 1, 2012, to January 1, 2022, by retrospectively reviewing the records from October 1, 2023, to November 1, 2023. 664 patients who underwent PDA closure, (n = 316) in the transcatheter closure group and (n = 348) patients in the surgical ligation group were included in this study.*

**RESULT:** *The surgical ligation group patients were younger, and more proportion of patients had severe pulmonary hypertension. Overall complications were significantly higher with surgical ligation compared with transcatheter closure ((112 (35.4% vs 286 (71.9%)), p-value = 0.001). Total mechanical ventilation time, intensive care unit(ICU) stay, and hospital stay were higher in the surgical ligation group with a p-value of 0.001 each.*

**CONCLUSION:** *Transcatheter closure of PDA has lower overall complications and shorter mechanical ventilation time, lower ICU stay, and lower hospital stay. Given the lower number of overall complications, transcatheter closure of PDA has to be considered for selected patients.*

**KEYWORDS:** *PDA, surgical ligation of PDA, Transcatheter closure of PDA, comparative study*

## INTRODUCTION

Ductus arteriosus is an important fetal structure that developed from the sixth left embryonic arch and serves as a passage between the left pulmonary artery and the aortic arch to relieve the right ventricle's afterload during fetal life(1). Its birth prevalence ranges from 0.87 to 1 per 1,000 live births and accounts for 10% of congenital cardiac disease(1–3). In normal-term babies, spontaneous closure of ductus arteriosus was anticipated to occur within 48 hours in 90% of cases and within 72 hours in 100% of instances(4).

Depending mainly on its size, the ductus arteriosus may persist even into later childhood or into adulthood due to the need for numerous factors in its spontaneous closure (4). Patent ductus arteriosus (PDA) if it is hemodynamically significant, can lead to several complications, such as heart failure brought on by increased pulmonary over circulation, aneurysmal dilatation of PDA with a risk of rupture, and in the long-term pulmonary obstructive illness (Eisenmenger syndrome). Infective endarteritis may also occur as a complication of small PDA(5,6). There are hence indications for PDA closure before the onset of the aforementioned complications. The indications are the presence of symptoms and left heart chamber dilatation regardless of the presence of symptoms(6).

The two management options for PDA are transcatheter closure and surgical ligation. Although both management options have complications and variations in outcomes across centers, transcatheter closure(TC) of PDA is on the rise in the developed world while surgical ligation(SL) is on the decline(6,7).

In developing countries, where closure is typically carried out in late childhood and adolescence, there isn't many researches done that compare the complication and overall in-hospital outcome of TL vs. SC. The few studies done in Pakistan and Indonesia that compared the outcome difference in patients who were managed with TC vs. SL showed that TC has lower complication, mortality, and length of hospital stay(8,9).

However, as far as we are aware there are only a few studies done in Africa that compare the immediate outcome of TC vs. SL of PDA. Therefore, the purpose of this study is to compare

the immediate outcomes of the two PDA closure techniques in patients who have undergone PDA closure in a cardiac center of Ethiopia.

## METHODS AND MATERIALS

**Study area and period:** The Cardiac Center of Ethiopia (CCE) is located in Addis Ababa, the capital of Ethiopia. It has offered free care to cardiac patients ever since it was established in 2012. It also provides both adult and pediatric cardiac surgeries as well as both adult and pediatric interventional procedures. The facility has five wards with ten beds each, one OR, one CATH lab, and one ICU with five beds. At least 50 adult and child patients are seen daily in this facility's outpatient department. The facility performs three cardiac operations and three interventional procedures each week. The hospital currently has 20 nurses working there, along with four cardiac and cardiothoracic surgeons, three pediatric cardiologists, and two adult cardiologists. This study was carried out in CCE from October 1, 2023 to November 1, 2023.

**Study design:** Comparative cross-sectional study

**Source population:** The source population consisted of all pediatric patients with PDA under the age of 18 who underwent TC or SL of PDA in the cardiac center of Ethiopia.

**Study population:** All PDA patients under the age of 18 who underwent PDA closure (TC or SL) in the cardiac center of Ethiopia between January 2012 and January 2022 were included in the study population.

**Inclusion and exclusion criteria:** All PDA patients under the age of 18 who had PDA closure (TC or SL) performed at the cardiac center in Ethiopia between January 2012 and January 2022 were included in the study. On the other hand, syndromic patients, patients with additional congenital heart disease to PDA, and patients with incompletely documented patient outcomes were excluded from this study.

### Procedure

**Transcatheter closure:** Patient selection for device closure is based on weight greater than 6 kg and age greater than 1 year, per hospital protocol. One to three millimeters more than the duct's

minimum diameter device size were used. Before transcatheter closure of the PDA, we obtained informed consent from the patient's parents, administered a prophylactic dose of intravenous ceftriaxone, used transthoracic echocardiography to confirm the diagnosis of PDA, and ruled out other associated congenital heart diseases and used general anesthesia for sedation. In all of our patients, the transcatheter procedure began with the femoral artery and vein being punctured, a 5Fr. femoral sheath being inserted, and then heparin being administered. A 5Fr. MPA2 catheter was inserted to measure the pressure in the right ventricle and pulmonary arteries. Aortography was performed after the descending aorta was catheterized with a 5 Fr. pigtail catheter. Images of the PDA were obtained using angiography using lateral and right lateral oblique views. The angiographic result guided the device choice in our setting. The delivery sheath was advanced using the femoral vein. In our center, ADO-1, ADO-2, Lifetech PDA device, Cocoon PDA device, PFM device, Amplatzer muscular VSD occluder, and coils were in use. Transthoracic echocardiography was performed to evaluate the remaining shunt after device deployment angiography. Following the procedure, the patients were monitored for complications for 12 hours in the hospital before discharge, and will be discharged receiving follow-up care two weeks later.

#### Surgical ligation

Likewise, before surgical ligation of PDA, we obtained informed consent from the patient's parents, administered a prophylactic dose of intravenous ceftriaxone, and used transthoracic echocardiography to confirm the diagnosis of PDA, and to rule out other associated congenital heart defects. General anesthesia for sedation was used in all cases. After that, a posterolateral incision was made in the left chest, double ligation of PDA, or division and double ligation of PDA, or double ligation with clipping with metallic clip or clipping with metallic clip alone were performed based on surgeon preference. A prophylactic chest tube was inserted and the patients were monitored for complications overnight and discharged the next day after being given an appointment after a week.

#### Study variables

**Dependent variables:** The difference in the immediate outcome of TC Vs SL of PDA

**Independent variable:** PDA closure types (TC or SL)

**Covariates:** Echocardiographic size of PDA, age at diagnosis, age at procedure, sex, weight at surgery, height at surgery, and presence of severe pulmonary hypertension

#### Definitions and operational definitions

**Postoperative or postprocedural complications** - the presence of any cardiac or extracardiac complications postoperatively or post-procedure in the hospital.

**Small residual PDA-** residual PDA of <1.5mm

**Moderate residual PDA-**residual PDA of 1.5-3mm

**Large residual PDA-**residual PDA of >3mm

**Mild Left ventricular dysfunction-** Left ventricular ejection fraction of 40-49%

**Moderate left ventricular dysfunction-** Left ventricular ejection fraction of 30-39%

**Severe left ventricular dysfunction-**Left ventricular ejection fraction of less than 30%

**Small pericardial effusion-**the maximum echo-free space between the heart and pericardium of <10mm in subcostal and apical four-chamber view

**Moderate pericardial effusion-** the maximum echo-free space between the heart and pericardium of 10-20mm in subcostal and apical four-chamber view

**Large pericardial effusion-** the maximum echo-free space between the heart and pericardium of greater than >20mm in subcostal and apical four-chamber view

**Small pleural effusion-**the maximum echo-free space between the lung and dome of diaphragm <10mm in subcostal view.

**Moderate pleural effusion-** the maximum echo-free space between the lung and dome of the diaphragm 10-20mm in the subcostal view

**Large pleural effusion-** the maximum echo-free space between the lung and dome of the diaphragm of greater than >20mm in subcostal view.

**Flow acceleration in the aortic arch left pulmonary artery, and the right pulmonary artery-** doppler velocity greater than 2m/s in the

aortic arch, left pulmonary artery, and right pulmonary artery respectively.

**Acute kidney injury**-absolute increase in serum creatinine of 0.3mg/dl or a 1.5-fold increase in serum creatinine from the baseline.

**Systemic hypertension**-blood pressure that was at or above the 95<sup>th</sup> percentile for children who are the same sex, age, and height.

**Pulmonary hypertension**-measured in a study by subtracting the systolic gradient of PDA in CW from the systolic pressure of the patient to get the systolic pulmonary pressure.

**Pulmonary hypertension crisis**-in a patient who had/developed pulmonary hypertension later /postoperatively or post device closure) presented with tachycardia, hypotension, poor perfusion, altered mental status, and enlarged liver.

**Low cardiac output patients** who presented with altered mental status, cold extremity, tachycardia or bradycardia, hypotension, low urine output(<0.5ml/kg/hr.), and metabolic acidosis.

**Immediate Outcome**- measured in this study by the presence of any complications, length of hospital stays, the presence of residual shunts, and death.

**Mortality**- death occurrence at any time before discharge from the hospital after post-surgery or post-procedure.

**Data collection procedure and tools:** Data was collected for a period of 1 month from October 1, 2023 to November 1, 2023. A structured questionnaire was used for data extraction. The questionnaire was adopted from the Society of Thoracic Surgeon version 3.1 form. The author did not have access to information that could identify individual participants during or after data collection.

**Data quality assurance:** To ensure the internal validity (accuracy and precision) of the study, maximum effort was taken to ensure the quality of data, to minimize errors and bias using the following measures, two days training for data collectors and supervisors was carried out to have a clear understanding about the objective of the study and data collection procedure.

The pre-testing of the structured format will be conducted on a 5% sample at Tasma Hospital (a private Hospital in Addis Ababa), who undergone

PDA closure for PDA patients, before data collection to assess the quality of the questionnaire. Process and structured format will be checked for completeness daily by immediate supervisors and the principal investigator. After checking for consistency and completeness, the supervisors submitted the filled questionnaire to the principal investigator who rechecked the questionnaire, to maintain the quality of data. Data was cleaned & entered by the principal investigator and strict daily field supervision and spot-checking were carried out.

**Data analysis:** The accuracy of the data was manually verified. The data was then cleansed and saved for consistency after being entered into the Epi info 7 program. The data was once again exported for analysis using SPSS version 28 and Microsoft Excel 13. After verifying the normality of continuous variables, appropriate descriptive statistics were performed. To verify normality, the Shapiro-Wilk test was applied. Categorical variables were described by frequency and percentage. Multivariable logistic regression was used to generate propensity scores based on the baseline characteristics of the patients in the SL and TC groups. The propensity scores multivariate logistic regression model used in the primary analyses considered the following variables: echocardiographic size of PDA, age at diagnosis, age at procedure, sex, weight at surgery, height at surgery, and presence of severe pulmonary hypertension. Using the inverse probability of treatment weighting (IPTW) by the propensity score and after adjusting for baseline variables, the Man U test, Chi-square test, and Fisher's exact test were used to compare immediate outcomes of TC and SL of PDA. The statistical significance was assessed using a 2-tailed p-value <0.05.

**Ethical consideration:** Before beginning the actual research, the ethical review committee and advisor gave their approval for the study. Hawassa University granted its ethical approval. The medical director of CCE was informed of the study's objectives and data from patient charts were extracted without using any personal identifiers to ensure confidentiality, and it was solely utilized for this study purpose.

**Ethical considerations:** Written informed consent was obtained from a research ethics review board at Saint Paul Millennium College to extract data from patients' medical records.

## RESULTS

**Socio-demographic characteristics:** The socio-demographic characteristics of both Groups, Group-TC, and Group-SL are presented in **Error! Reference source not found.** In this study, 316 patients (47.6%) had TC, while 348 patients

(52.4%) had SL of PDA. At the time of surgery, the median age for Group 1-TC was 3.8 (IQR: 1.6–5.6) and for Group 2-SC, it was 3 (IQR: 1.7–6; P = 0.15). Females made up 178(56.3%) in Group-TC and 213(61.8%) in Group-SL. Age at diagnosis, weight at surgery, and height at surgery, presence of severe PAH before surgery showed statistical differences between the two groups (TC and SC) with P values of 0.04, 0.02, 0.002, and 0.001 respectively.

Table 1: Presents the socio-demographic and basic characteristics of patients who underwent PDA closure at the Cardiac Center of Ethiopia, 2012-2022.

| Variables  | TC<br>N=316 (47.6%) | SC<br>N=348 (52.4%) | P value |
|--|---------------------|---------------------|---------|
| Age at diagnosis, median (IQR) (year)            | 3(1.6-5.6)          | 2.4(1-5)            | 0.04    |
| Age at procedure, median (IQR)(year)             | 3.8(1.6- 6)         | 3(1.7-6)            | 0.15    |
| Sex  |                     |                     | 0.20    |
| Male n (%)                                       | 138(43.7)           | 135(38.8)           |         |
| Female n (%)                                     | 178(56.3)           | 213(61.8)           |         |
| Weight at surgery, median (IQR) (Kg)             | 12(10-16)           | 11(10-16)           | 0.02    |
| Height at surgery, median (IQR)(cm)              | 100(92-107)         | 98(83-107)          | 0.002   |
| Echocardiographic size of PDA, median (IQR) (mm) | 5(4-8)              | 6(4-7)              | 0.06    |
| Angiographic size of PDA, median (IQR)(mm)       | 4.5(3.5-7)          | NA                  | -       |
| Severe pulmonary hypertension                    |                     |                     | 0.001   |
| Yes n (%)  | 96(30.4)            | 184(52.9)           |         |
| No n (%)   | 220(69.6)           | 164(47.1)           |         |

## Complications of PDA closure:

Table 2 demonstrates the two groups' percentages of various complications (SL group and TC group). Patients in Group SL had higher overall complications compared to Group TC. The SL group had a higher magnitude of all complications

except flow acceleration in the RPA, LPA, and descending aorta. Encroachment of the device into the LPA and descending aorta caused flow acceleration in those vessels, whereas embolization of the device into the RPA caused flow acceleration in that vessel.(Table2, Figure 1)


Table 2: shows a comparison of complications of patients who underwent PDA closure in the cardiac center of Ethiopia, 2012-2022.

| Complications                 | Group-TC 316(47.6%) | Group-SL 348 (52.4%) | P value |
|-------------------------------|---------------------|----------------------|---------|
| Mild LV dysfunction           | 14(4.4)             | 34(9.8)              | 0.001   |
| Moderate LV dysfunction       | 12(3.8)             | 18(5.2)              | 0.62    |
| Severe LV dysfunction         | 2(0.6%)             | 6(1.7)               | 0.99    |
| small pericardial effusion    | 2(0.6)              | 8(2.3)               | 0.01    |
| Moderate pericardial effusion | 0(0)                | 2(0.6)               | 0.99    |
| Moderate pleural effusion     | 0(0)                | 2(0.6)               | 0.99    |
| Pneumothorax                  | 2(0.6)              | 2(0.6)               | 0.34    |
| Chylothorax                   | 0(0)                | 4(1.1)               | 0.99    |
| Hemothorax                    | 0(0)                | 4(1.1)               | 0.99    |

|                              |        |        |      |
|------------------------------|--------|--------|------|
| Flow acceleration in the LPA | 6(1.9) | 4(1.1) | 0.36 |
| Flow acceleration in the RPA | 6(1.9) | 4(1.1) | 0.03 |

Table 1: Continued...

|  |           |           |       |
|--|-----------|-----------|-------|
| Flow acceleration over the aortic arch | 8(2.5)    | 4(1.1)    | 0.01  |
| Ascending aorta to RPA fistula         | 0(0)      | 2(0.6)    | 0.99  |
| Hypertension                           | 6(1.9)    | 40(11.5)  | 0.001 |
| Pulmonary hypertension crisis          | 0(0)      | 2(0.6)    | 0.99  |
| Hyperkalemia                           | 0(0)      | 2(0.6)    | 0.99  |
| Hypokalemia                            | 0(0)      | 8(2.3)    | 0.99  |
| Hyperglycemia                          | 0(0)      | 6(1.7)    | 0.98  |
| Bleeding that needs a transfusion      | 7(2.2)    | 12(3.4)   | 0.13  |
| Sepsis                                 | 0(0)      | 2(0.6)    | 0.99  |
| Acute kidney injury                    | 0(0)      | 8(2.3)    | 0.99  |
| Metabolic acidosis                     | 0(0)      | 10(2.9)   | 0.99  |
| Metabolic alkalosis                    | 0(0)      | 2(0.6)    | 0.99  |
| Thrombocytopenia                       | 0(0)      | 2(0.6)    | 0.99  |
| Low cardiac output                     | 0(0)      | 4(1.1)    | 0.99  |
| Femoral pulse loss                     | 2(0.6)    | 0(0)      | 0.99  |
| Chest wall hematoma                    | 0(0)      | 2(0.6)    | 0.99  |
| Atelectasis                            | 4(1.3)    | 8(2.3)    | 0.30  |
| Paraplegia                             | 0(0)      | 4(1.1)    | 0.98  |
| One complication n (%)                 | 72(37.3)  | 121(62.7) | 0.001 |
| Two complications                      | 14(8.8)   | 50(79.4)  |       |
| Three or more complications            | 4(3.8)    | 19(82.6)  |       |
| Overall complication n (%)             | 112(35.4) | 286(71.9) | 0.001 |
| Opioid use                             | 3(0.94)   | 55(15.8)  | 0.001 |



**Figure 1:** Demonstrating the number of complications of TC and SL of PDA in patients who have undergone PDA closure in the Cardiac Center of Ethiopia, 2012-2022

**Comparison between TC and SC outcome:** Differences in total length of mechanical ventilation, length of ICU stay, and length of hospital stay were statistically significant between Group-TC and Group-SC patients, all stays were more in Group-SC patients. There was no significant difference in the proportion of mortality between the two groups Table 3.

Table 3; presents the outcome of TC vs SL in patients who have undergone PDA closure in the Cardiac Center of Ethiopia, 2012-2023.

| Outcome  | TC        | SL       | P value |
|--|-----------|----------|---------|
| Length of mechanical ventilation median (IQR)(hr.) | 4(3-6.75) | 9(4-13)  | 0.001   |
| Length of ICU stay median (IQR)(days)              | 1(1-3)    | 3(1-5)   | 0.001   |
| Length of hospital stay median (IQR)(days)         | 2(2-2.1)  | 4(2-6)   | 0.001   |
| Failed device closure n (%)                        | 6(1.9%)   | -        | -       |
| small residual PDA                                 | 34(10.8)  | 68(19.5) | 0.01    |
| Moderate residual PDA                              | 4(1.3)    | 12(3.4)  | 0.02    |
| Death n (%)  | 1(0.3)    | 0        | 0.99    |

## DISCUSSION

Our study compares the immediate outcomes of SL and TC closure of PDA in a cardiac center in Ethiopia. Our finding showed that the SL group had statistically significantly greater percentages of overall complications, mild LV dysfunction, mild pericardial effusion, systemic hypertension, and a higher need for opioids as a complication. Regarding the presence of residual PDA and hospital stays, our study also revealed that the SL group experienced milder and more moderate residual PDA and longer ICU and hospital stays. In addition, we reported a higher percentage of flow acceleration in RPA and the descending aorta in the TC group.

Similar studies from China, Brazil, and Nigeria corroborated this study's finding that there were more overall complications in the SL group compared to the TC group(10–12). Contrary to this, however, one study from the USA found that TC complications were higher than SL complications(13). Additionally, research from Indonesia revealed no differences in complications magnitude between the two groups(9). The age difference between study participants and the experience of professionals in various nations can both be used to explain the discrepancy in reporting the magnitude of complications between SL and TC.

The higher LV dysfunction percentage in SL found in our study is supported by a previous study that was carried out in Ethiopia, where 42.9% of patients experienced mild LV dysfunction after surgery, as opposed to studies done in Korea and India, where only 25% and 18.6% of patients experienced the same complication(14–16). The decrease in LV preload and rise in LV afterload following PDA ligation account for the decline in LV function. Because PDA causes a left-to-right shunt and increases LV preload after ligation, the LV preload decreases noticeably. The increase in afterload is caused by the fact that, before ligation, the LV pumps blood to both the high-resistant aorta and low-resistance pulmonary circulation. However, after closure, the LV only pumped blood against the high-resistance aorta. Further study is needed since it is unknown why surgical ligation causes LV dysfunction to develop more frequently than TC.

Only a few studies in device closure but none in surgical ligation demonstrated flow acceleration in the RPA. In comparison to studies conducted in Pakistan and South Africa, which revealed flow acceleration in the RPA of 2% and 3.1%, respectively, our study found a comparable figure (1.9%)(17,18). Due to the RPA's anatomical distance from the PDA, the rarity of flow acceleration in RPA following surgical closure can

be explained. Even though the RPA is anatomically far away from the PDA, it happens frequently during device closure that the device may embolize to the RPA.

Acceleration of blood flow in the descending aorta as a result of device embolization or encroachment of the device to the descending aorta, as in our study, has been documented in numerous studies. It has been reported in studies in the USA (1.9%) and (0.3%)(19), Saudi Arabia (7.4%), Sudan (0.7%), Egypt (0.3%), and in our study (2.5%)(20–23). After surgical PDA ligation, there is a possible risk of inadvertent injury to the descending aorta (24). But reports are very rare.

Even though PDA is an extracardiac structure, there have been reports of pericardial injury and pericardial effusion in other studies, such as those conducted in the UK and Finland, with pericardial effusion proportions of 0.3% and 1%, respectively, which are lower than the 3.3% described in our study(25,26). This variation in pericardial effusion prevalence following surgical PDA ligation can be attributed to the surgeon's experience. In our research, there were only 2 patients in the device group who experienced pericardial effusion; nevertheless, there have been no reports of pericardial effusion following device closure of PDA. This can be a result of the chest device technique not involving any external manipulation.

A study from Korea showed a significant number of patients developed systemic hypertension after PDA surgical ligation (27). Our report of 11.5% systemic hypertension following PDA ligation is higher than that reported from a study in Canada (4.7%) but lower than that from a study in Brazil (67%)(12,28). A possible cause is sympathetic nervous system hyperactivity, which led to a significant increase in catecholamines. There are limited reports of systemic hypertension following TC; one study from Nigeria found 6.3% of systemic hypertension following device closure, while Brazilian research did not find any cases of systemic hypertension(10)(12). Therefore, the manipulation of the aortic arch that enhances the sympathetic surge is high in SL compared to TC, which can be used to explain why there is a higher prevalence of systemic hypertension following SL.

Comparable to our study, Patients in a Brazilian comparison study who underwent

surgical ligation needed more opioids than those who underwent transcatheter closure (12). This can be explained by the fact that the expected pain score is high for surgical ligation because it is more invasive than TC.

Similar to a study conducted in Pakistan, our research found that the surgical group had more residual PDA than the TC group did (8). However, research from the USA and China disputes our findings (13)(11). Furthermore, in contrast to our data, another Chinese study found no variation in the magnitude of residual in the TC and SC (29). This discrepancy in residual PDA reporting may be caused by the fact that surgical expertise and interventional cardiology ability are the key determinants of residual PDA occurrence.

Studies from the United States, Brazil, Sudan, China, Indonesia, and Pakistan corroborated our study's findings that patients who underwent surgical ligation had longer hospital stays and stays in the intensive care unit (8,9,12,21,30). The overall complications are more prevalent in SL of PDA than TC of PDA, which explains this.

TC of PDA has fewer overall complications, shorter hospital stays, fewer stays in the intensive care unit, and fewer stays on mechanical ventilation. However, TC of PDA has more complications in major vessels such as flow acceleration in the arch, LPA, RPA, and absence of a pulse in the femoral artery. Given the lower number of overall complications, shorter hospital stays, fewer stays in the intensive care unit, and lower number of days on mechanical ventilation, TC of PDA has to be considered for selected patients.

Transcatheter Closure (TC) of Patent Ductus Arteriosus (PDA) presents several advantages over surgical closure, including fewer overall complications, shorter hospital stays, fewer stays in the intensive care unit (ICU), and reduced days on mechanical ventilation. However, it's crucial to acknowledge that TC of PDA may entail certain specific complications related to major vessels, such as flow acceleration in the aortic arch, left pulmonary artery (LPA), right pulmonary artery (RPA), and potential absence of a pulse in the femoral artery. Considering the substantial benefits in terms of reduced complications and shorter



hospital stays, TC of PDA should be strongly considered for carefully selected patients.

This study has few limitations. The cross-sectional nature of the study design may lead to limitations in identifying complications associated with TC and SL closure of PDA that can be detected in the medium to long term, and its retrospective nature can lead to classification bias. Additionally, because this was a single-center study, generalizations cannot be made. However, this study is important for improving the quality of TC and SL closure of PDA in Ethiopia because it provides important baseline data facilitates comparison of the centers' results with those of other centers, and can help make management decisions (select TC or SL PDA for PDA closure) and help establish funding priorities and resource allocation during PDA closure.

#### ACKNOWLEDGEMENT

We would like to acknowledge the participants and data collectors for providing us with consent to share their history and collect the data. We also wish to express our gratitude to the Cardiac Center of Ethiopia for allowing the collection of data and to Hawassa University School of Medicine and Health Science providing ethical clearance.

#### REFERENCES

- Schneider DJ. The patent ductus arteriosus in term infants, children, and adults. In *Seminars in perinatology* 2012 Apr 1 (Vol. 36, No. 2, pp. 146-153). WB Saunders.
- Liu Y, Chen S, Zühlke L, Black GC, Choy MK, Li N, Keavney BD. Global birth prevalence of congenital heart defects 1970–2017: updated systematic review and meta-analysis of 260 studies. *International journal of epidemiology*. 2019 Apr 1;48(2):455-63.
- Van Der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, Roos-Hesselink JW. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. *Journal of the American College of Cardiology*. 2011 Nov 15;5.
- Backes CH, Hill KD, Shelton EL, Slaughter JL, Lewis TR, Weisz DE, Mah ML, Bhombal S, Smith CV, McNamara PJ, Benitz WE. Patent ductus arteriosus: a contemporary perspective for the Pediatric and adult cardiac care provider. *Journal of the American Heart Association*. 2022 Sep 6;11(17): e025784.
- Gournay V. The ductus arteriosus: physiology, regulation, and functional and congenital anomalies. *Archives of cardiovascular diseases*. 2011 Nov 1;104(11):578-85.
- Schneider DJ, Moore JW. Patent ductus arteriosus. *Circulation*. 2006 Oct 24;114(17):1873-82.
- Reese J, Scott TA, Patrick SW. Changing patterns of patent ductus arteriosus surgical ligation in the United States. In *Seminars in perinatology* 2018 Jun 1 (Vol. 42, No. 4, pp. 253-261). WB Saunders.
- Zulqarnain A, Younas M, Waqar T, Beg A, Asma T, Baig MA. Comparison of effectiveness and cost of patent ductus arteriosus device occlusion versus surgical ligation of patent ductus arteriosus. *Pakistan Journal of Medical Sciences*. 2016 Jul;32(4):974.
- Djer MM, Mochammading M, Said M. Transcatheter vs. surgical closure of patent ductus arteriosus: outcomes and cost analysis. *Paediatrica Indonesiana*. 2013 Aug 31;53(4):239-44.
- Animasahun BA, Adekunle MO, Falase O, Gidado MT, Kusimo OY, Sanusi MO, Johnson A. Is transcatheter closure superior to surgical ligation of patent ductus arteriosus among Nigerian Children?. *African Journal of Paediatric Surgery: AJPS*. 2018 Apr;15(2):100.
- Chen ZY, Wu LM, Luo YK, Lin CG, Peng YF, Zhen XC, Chen LL. Comparison of long-term clinical outcome between transcatheter Amplatzer occlusion and surgical closure of isolated patent ductus arteriosus. *Chinese medical journal*. 2009 May 20;122(10):1123-7.
- Costa RN, Pereira FL, Ribeiro MS, Pedra SR, Succi F, Marques P, Jatene MB, Fontes VF, Pedra CA. Percutaneous vs. surgical treatment of patent ductus arteriosus in children and adolescents. *Revista Brasileira de Cardiologia Invasiva*. 2012;20:315-23.
- Kim HS, Schechter MA, Manning PB, Eghtesady P, Balzer DT, Shahanavaz S, Rockefeller TA, Abarbanell AM. Surgical

- versus percutaneous closure of PDA in preterm infants: procedural charges and outcomes. *Journal of Surgical Research*. 2019 Nov 1;243:41-6.
14. Tilahun B, Tefera E. Transient left ventricular systolic dysfunction following surgical closure of large patent ductus arteriosus among children and adolescents operated at the cardiac centre, Ethiopia. *Journal of cardiothoracic surgery*. 2013 Dec;8(1):1-5.
  15. Gupta SK, Krishnamoorthy KM, Tharakan JA, Sivasankaran S, Sanjay G, Bijulal S, Anees T. Percutaneous closure of patent ductus arteriosus in children: Immediate and short-term changes in left ventricular systolic and diastolic function. *Annals of pediatric cardiology*. 2011 Jul;4(2):139.
  16. Kim YH, Choi HJ, Cho Y, Lee SB, Hyun MC. Transient left ventricular dysfunction after percutaneous patent ductus arteriosus closure in children. *Korean Circulation Journal*. 2008 Nov 1;38(11):596-600.
  17. Khan AM, Ullah Z, Ilyas S, Wazir HD, Rehman Y, Hussain I, Sadia H, Wazir Sr HD. The outcome of trans-catheter closure of patent ductus arteriosus: a single-center experience. *Cureus*. 2022 Jan 24;14(1).
  18. Pepeta L, Greyling A, Nxele MF, Makrexeni ZM. Patent ductus arteriosus closure using Occlutech® duct occluder, experience in Port Elizabeth, South Africa. *Annals of Pediatric Cardiology*. 2017 May;10(2):131.
  19. Faella HJ, Hijazi ZM. Closure of the patent ductus arteriosus with the Amplatzer PDA device: immediate results of the international clinical trial. *Catheterization and cardiovascular interventions*. 2000 Sep;51(1):50-4.
  20. Nour A, Abdelrazik Y, Huessin S, Kamel H. Safety and efficacy of percutaneous patent ductus arteriosus closure: a multicenter Egyptian experience. *The Egyptian Heart Journal*. 2022 Dec;74(1):1-7.
  21. Elsheikh AE, Hassan SE, El Siddig AM, Ahmed ME, Hussein ST, ELjack MM. Patent Ductus Arteriosus Device or Surgical Closure: the Role of Charity Missions Where the Resources Are Limited.
  22. Azhar AS, Abd El-Azim AA, Habib HS. Transcatheter closure of patent ductus arteriosus: Evaluating the effect of the learning curve on the outcome. *Annals of Pediatric Cardiology*. 2009 Jan;2(1):36.
  23. Backes CH, Cheatham SL, Deyo GM, Leopold S, Ball MK, Smith CV, Garg V, Holzer RJ, Cheatham JP, Berman DP. Percutaneous patent ductus arteriosus (PDA) closure in very preterm infants: feasibility and complications. *Journal of the American Heart Association*. 2016 Feb 12;5(2):e002923.
  24. Weisz DE, McNamara PJ. Patent ductus arteriosus ligation and adverse outcomes: causality or bias?. *Journal of clinical neonatology*. 2014 Apr;3(2):67.
  25. Niinikoski H, Alanen M, Parvinen T, Aantaa R, Ekblad H, Kero P. Surgical closure of patent ductus arteriosus in very-low-birth-weight infants. *Pediatric surgery international*. 2001 Jul;17:338-41.
  26. Kang SL, Jivanji S, Mehta C, Tometzki AJ, Martin RP. P16 Safety and efficacy of transcatheter PDA occlusion in infants less than 6kgs.
  27. Chang YH, Lee JY, Kim JE, Kim JY, Youn Y, Lee EJ, Moon S, Lee JY, Sung IK. The Aristotle score predicts mortality after surgery of patent ductus arteriosus in preterm infants. *The Annals of Thoracic Surgery*. 2013 Sep 1;96(3):879-84.
  28. Forbes TL, Evans MG. Optimal elective management of patent ductus arteriosus in the older child. *Journal of pediatric surgery*. 1996 Jun 1;31(6):765-7.
  29. Chen Z, Chen L, Wu L. Transcatheter amplatzer occlusion and surgical closure of patent ductus arteriosus: comparison of effectiveness and costs in a low-income country. *Pediatric cardiology*. 2009 Aug;30:781-5.
  30. Kuntz MT, Staffa SJ, Graham D, Faraoni D, Levy P, DiNardo J, Maschietto N, Nasr VG. Trend and outcomes for surgical versus transcatheter patent ductus arteriosus closure in neonates and infants at US children's hospitals. *Journal of the American Heart Association*. 2022 Jan 4;11(1): e022776.
-

